{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:16:43Z","timestamp":1770905803880,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"SpyGlass Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40123-026-01313-4","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T12:52:04Z","timestamp":1769950324000},"page":"855-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective Pilot Study of Sustained Release Bimatoprost Implant with SpyGlass Intraocular Lens: 3-Year Results"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct07154797","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07154810","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7362-0038","authenticated-orcid":false,"given":"Nicholas E.","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Robles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeya K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malik Y.","family":"Kahook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan M.","family":"Radcliffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"issue":"4","key":"1313_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","volume":"127","author":"PA Newman-Casey","year":"2020","unstructured":"Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC. The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology. 2020;127(4):477\u201383.","journal-title":"Ophthalmology"},{"issue":"11","key":"1313_CR2","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1185\/03007995.2013.833898","volume":"29","author":"GF Schwartz","year":"2013","unstructured":"Schwartz GF, Hollander DA, Williams JM. Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertension. Curr Med Res Opin. 2013;29(11):1515\u201322.","journal-title":"Curr Med Res Opin"},{"issue":"11 Suppl","key":"1313_CR3","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.ophtha.2009.06.024","volume":"116","author":"JC Tsai","year":"2009","unstructured":"Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116(11 Suppl):S30-36.","journal-title":"Ophthalmology"},{"issue":"6","key":"1313_CR4","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s40123-023-00831-9","volume":"12","author":"NM Radcliffe","year":"2023","unstructured":"Radcliffe NM, Shah M, Samuelson TW. Challenging the \u201cTopical Medications-First\u201d approach to glaucoma: a treatment paradigm in evolution. Ophthalmol Ther. 2023;12(6):2823\u201339.","journal-title":"Ophthalmol Ther"},{"issue":"17","key":"1313_CR5","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s40265-021-01624-9","volume":"81","author":"J Bacharach","year":"2021","unstructured":"Bacharach J, Tatham A, Ferguson G, et al. Phase\u00a03, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81(17):2017\u201333.","journal-title":"Drugs"},{"issue":"3","key":"1313_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/vision7030054","volume":"7","author":"M Balas","year":"2023","unstructured":"Balas M, Mathew DJ. Minimally invasive glaucoma surgery: a review of the literature. Vision (Basel). 2023. https:\/\/doi.org\/10.3390\/vision7030054.","journal-title":"Vision (Basel)"},{"issue":"2","key":"1313_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","volume":"130","author":"G Gazzard","year":"2023","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Laser in glaucoma and ocular hypertension (LiGHT) trial: six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology. 2023;130(2):139\u201351.","journal-title":"Ophthalmology"},{"issue":"9","key":"1313_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ophtha.2024.02.022","volume":"131","author":"SR Sarkisian Jr","year":"2024","unstructured":"Sarkisian SR Jr, Ang RE, Lee AM, et al. Phase\u00a03 randomized clinical trial of the safety and efficacy of travoprost intraocular implant in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2024;131(9):1021\u201332.","journal-title":"Ophthalmology"},{"key":"1313_CR9","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.ophtha.2022.07.003","volume":"129","author":"SJ Gedde","year":"2022","unstructured":"Gedde SJ, Feuer WJ, Lim KS, et al. Treatment outcomes in the primary tube versus trabeculectomy (PTVT) study after 5\u00a0years of follow-up. Ophthalmology. 2022;129:1344\u201356.","journal-title":"Ophthalmology"},{"issue":"5","key":"1313_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/bjophthalmol-2013-304256","volume":"98","author":"K Kaplowitz","year":"2014","unstructured":"Kaplowitz K, Schuman JS, Loewen NA. Techniques and outcomes of minimally invasive trabecular ablation and bypass surgery. Br J Ophthalmol. 2014;98(5):579\u201385.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1313_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ophtha.2020.06.051","volume":"128","author":"S Rathi","year":"2021","unstructured":"Rathi S, Andrews CA, Greenfield DS, Stein JD. Trends in glaucoma surgeries performed by glaucoma subspecialists versus nonsubspecialists on Medicare beneficiaries from 2008 through 2016. Ophthalmology. 2021;128(1):30\u20138.","journal-title":"Ophthalmology"},{"issue":"4","key":"1313_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/j.jcrs.0000000000001365","volume":"50","author":"IIK Ahmed","year":"2024","unstructured":"Ahmed IIK, Sheybani A, De Francesco T, Samuelson TW. Corneal endothelial safety profile in minimally invasive glaucoma surgery. J Cataract Refract Surg. 2024;50(4):369\u201377.","journal-title":"J Cataract Refract Surg"},{"issue":"2","key":"1313_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/ICU.0000000000001110","volume":"36","author":"AP Mai","year":"2025","unstructured":"Mai AP, Ferguson TJ, Radcliffe N. New treatments for glaucoma. Curr Opin Ophthalmol. 2025;36(2):135\u20139.","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"1313_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/archopht.1988.01060130356020","volume":"106","author":"LT Chylack Jr","year":"1988","unstructured":"Chylack LT Jr, Leske MC, Sperduto R, Khu P, McCarthy D. Lens opacities classification system. Arch Ophthalmol. 1988;106(3):330\u20134.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"1313_CR15","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1167\/iovs.05-1253","volume":"47","author":"L Quaranta","year":"2006","unstructured":"Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47(7):2917\u201323.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1313_CR16","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0002-9394(00)00930-2","volume":"131","author":"WC Stewart","year":"2001","unstructured":"Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. Am J Ophthalmol. 2001;131(6):798\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1313_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/jop.1995.11.107","volume":"11","author":"YJ Hong","year":"1995","unstructured":"Hong YJ, Shin DH, Ahn BH, McCarty B. Intraocular pressure after a two-week washout following long-term timolol or levobunolol. J Ocul Pharmacol Ther. 1995;11(2):107\u201312.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"1313_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ophtha.2019.03.006","volume":"126","author":"TW Samuelson","year":"2019","unstructured":"Samuelson TW, Sarkisian SR Jr, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811\u201321.","journal-title":"Ophthalmology"},{"issue":"3","key":"1313_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ophtha.2010.07.007","volume":"118","author":"TW Samuelson","year":"2011","unstructured":"Samuelson TWMD, Katz LJMD, Wells JMP, Duh Y-JP, Giamporcaro JEBS. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118(3):459\u201367.","journal-title":"Ophthalmology"},{"issue":"7","key":"1313_CR20","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ophtha.2015.03.031","volume":"122","author":"N Pfeiffer","year":"2015","unstructured":"Pfeiffer N, Garcia-Feijoo J, Martinez-de-la-Casa JM, et al. A randomized trial of a Schlemm\u2019s canal microstent with phacoemulsification for reducing intraocular pressure in open-angle glaucoma. Ophthalmology. 2015;122(7):1283\u201393.","journal-title":"Ophthalmology"},{"issue":"1","key":"1313_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ophtha.2018.05.012","volume":"126","author":"TW Samuelson","year":"2019","unstructured":"Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON Study. Ophthalmology. 2019;126(1):29\u201337.","journal-title":"Ophthalmology"},{"issue":"3","key":"1313_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ophtha.2023.10.009","volume":"131","author":"GM Richter","year":"2024","unstructured":"Richter GM, Takusagawa HL, Sit AJ, et al. Trabecular procedures combined with cataract surgery for open-angle glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2024;131(3):370\u201382.","journal-title":"Ophthalmology"},{"issue":"10","key":"1313_CR23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jcrs.2018.07.015","volume":"44","author":"ED Donnenfeld","year":"2018","unstructured":"Donnenfeld ED, Solomon KD, Matossian C. Safety of IBI-10090 for inflammation associated with cataract surgery: phase\u00a03 multicenter study. J Cataract Refract Surg. 2018;44(10):1236\u201346.","journal-title":"J Cataract Refract Surg"},{"issue":"3","key":"1313_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/ICO.0000000000001826","volume":"38","author":"T Ianchulev","year":"2019","unstructured":"Ianchulev T, Lane S, Masis M, et al. Corneal endothelial cell density and morphology after phacoemulsification in patients with primary open-angle glaucoma and cataracts: 2-year results of a randomized multicenter trial. Cornea. 2019;38(3):325\u201331.","journal-title":"Cornea"},{"issue":"7","key":"1313_CR25","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/17425247.2023.2219053","volume":"20","author":"ZK Al-Qaysi","year":"2023","unstructured":"Al-Qaysi ZK, Beadham IG, Schwikkard SL, Bear JC, Al-Kinani AA, Alany RG. Sustained release ocular drug delivery systems for glaucoma therapy. Expert Opin Drug Deliv. 2023;20(7):905\u201319.","journal-title":"Expert Opin Drug Deliv"},{"issue":"8","key":"1313_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/IJG.0000000000002386","volume":"33","author":"K Benekos","year":"2024","unstructured":"Benekos K, Katsanos A, Haidich AB, Dastiridou A, Nikolaidou A, Konstas AG. The effect of phacoemulsification on the intraocular pressure of patients with open angle glaucoma: a systematic review and meta-analysis. J Glaucoma. 2024;33(8):576\u201386.","journal-title":"J Glaucoma"},{"key":"1313_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ajo.2022.09.006","volume":"245","author":"AL Rothman","year":"2023","unstructured":"Rothman AL, Chang TC, Lum F, Vanner EA. Intraocular pressure changes following stand-alone phacoemulsification: an IRIS(\u024c) registry analysis. Am J Ophthalmol. 2023;245:25\u201336.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1313_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ophtha.2020.07.016","volume":"128","author":"K Mansouri","year":"2021","unstructured":"Mansouri K, Rao HL, Weinreb RN. Short-term and long-term variability of intraocular pressure measured with an intraocular telemetry sensor in patients with glaucoma. Ophthalmology. 2021;128(2):227\u201333.","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01313-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01313-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01313-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:25:50Z","timestamp":1770902750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01313-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01313-4","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicholas E Tan: SpyGlass Pharma\u2014consultant. Gregory Katz: SpyGlass Pharma\u2014medical monitor, investigator; Alcon\u2014consultant, speaker; Bausch\u2009+\u2009Lomb\u2014consultant, speaker; Eyenovia\u2014consultant; New World Medical\u2014consultant; Sun Pharma\u2014consultant. Marco Robles: SpyGlass Pharma\u2014consultant, investigator; Aquea Health\u2014consultant, investigator, shareholder; Bausch\u2009+\u2009Lomb\u2014consultant, investigator; Glaukos\u2014consultant, investigator; iSTAR Medical\u2014consultant, investigator; New World Medical\u2014consultant, investigator; ViaLase\u2014consultant, investigator, shareholder. Preeya K Gupta: SpyGlass Pharma\u2014consultant, medical advisory board member, shareholder; Abbvie\u2014consultant; Alcon\u2014consultant; Aldeyra\u2014consultant; Azura\u2014consultant, shareholder; Bausch\u2009+\u2009Lomb\u2014consultant; Dompe\u2014consultant; Expert Opinion\u2014consultant, shareholder; HanAll Biopharma\u2014consultant; J&J Vision\u2014consultant; Kala\u2014consultant; Mazado\u2014consultant; Nordic Pharma\u2014consultant; Ocular Science\u2014consultant; Oculis\u2014consultant; Orasis\u2014consultant, shareholder; Sight Sciences\u2014consultant; Science Based Health\u2014consultant; Surface Ophthalmics\u2014consultant, shareholder; Tarsus\u2014consultant, shareholder; Tear Clear\u2014consultant, shareholder; Thea\u2014consultant; Tissue Tech, Inc\u2014consultant; Trukera\u2014consultant; Viatris\u2014consultant; Visionology\u2014consultant, shareholder; Vital Tears\u2014consultant; Zeiss\u2014consultant. Malik Kahook: SpyGlass Pharma\u2014president, patent royalties; Alcon\u2014patent royalties; FCI Ophthalmics\u2014consultant, patent royalties; New World Medical\u2014consultant, patent royalties. Glenn Sussman: SpyGlass Pharma\u2014employee. Paul Yoo: SpyGlass Pharma\u2014employee. Nathan M Radcliffe: SpyGlass Pharma\u2014consultant, medical advisory board member, shareholder; Alcon Laboratories\u2014consultant, speaker; Aldeyra Therapeutics\u2014consultant; Alimera Sciences\u2014consultant, speaker; Allergan\u2014consultant, speaker, grant support; Avellino Labs\u2014consultant; Bausch\u2009+\u2009Lomb\u2014consultant, speaker; Beaver-Visitec International\u2014consultant; Belkin Laser\u2014consultant; Carl Zeiss Meditec\u2014consultant; Dompe\u2014consultant; Elios Vision\u2014consultant; Ellex\u2014consultant, speaker; EyePoint Pharmaceuticals\u2014consultant; Glaukos Corporation\u2014consultant, speaker; ImprimisRx\u2014consultant; Iridex\u2014consultant, speaker; IrisVision\u2014consultant; Iveric Bio\u2014consultant; Kala Pharmaceuticals\u2014consultant, speaker; Lumenis Vision\u2014consultant, speaker; New World Medical\u2014consultant, speaker; Novartis Pharma AG\u2014consultant, speaker; Ocular Therapeutix\u2014consultant, grant support; Omeros Corporation\u2014consultant; Orasis Pharmaceuticals\u2014consultant; Quantel Medical\u2014consultant; Rayner\u2014consultant, speaker; Reichert\u2014consultant, speaker; Santen\u2014consultant; Shire\u2014consultant; Tarsus Pharmaceuticals\u2014consultant; TearClear\u2014consultant, shareholder; Thea\u2014consultant; ViaLase\u00a0Inc\u2014consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the National Health Research Ethics Committee in El Salvador (CNEIS\/2022\/01H). The study was conducted in accordance with the tenets of the Declaration of Helsinki and subsequent amendments. Written informed consent was obtained from all subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}